Threshold Pharmaceuticals to Participate in Two Investor Conferences i

    Business Editors/Health/Medical Writers
    CIBC World Markets Annual Biotechnology and Specialty
    Pharmaceuticals Conference
    BioCentury Future Leaders in the Biotech Industry

    REDWOOD CITY, Calif.--(BUSINESS WIRE)--March 31, 2005--Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that it will present at the following investor conferences in April 2005:

CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference Threshold's President, George Tidmarsh, M.D., Ph.D., will present at 9:30 a.m. Eastern Time on Tuesday, April 5, 2005 at The Millennium Broadway Hotel in New York.

BioCentury Future Leaders in the Biotech Industry Threshold's Chief Executive Officer, Barry Selick, Ph.D., will present at 3:20 p.m. Eastern Time on Thursday, April 7, 2005 at the Millennium Broadway Hotel in New York.

To access the live audio broadcasts or the subsequent archived recordings please log onto the following websites:

CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference http://www.veracast.com/webcasts/cibcwm/biotech05/41203355.cfm

BioCentury Future Leaders in the Biotech Industry http://www.thresholdpharm.com

    Please connect to the websites several minutes prior to the start of the presentations to ensure adequate time for any software download that may be necessary.

    About Threshold Pharmaceuticals

    Threshold is a biotechnology company focused on the discovery and development of small molecule therapeutics based on Metabolic Targeting, a powerful scientific approach that offers broad potential to treat most solid tumors and certain other diseases. By selectively targeting tumor cells, The Company is building a pipeline of drug candidates that hold promise to be more effective and less toxic to healthy tissues than conventional drugs. Threshold's initial clinical focus is the treatment of cancer and benign prostatic hyperplasia, or BPH, a disease characterized by overgrowth of the prostate. For additional information, please visit http://www.thresholdpharm.com.

--30--JR/sf*

CONTACT: Threshold Pharmaceuticals, Inc. Denise Powell, 650-474-8300 (Investor) dpowell@thresholdpharm.com or Access Communications Kim Paone, 917-522-3528 (Media) kpaone@accesspr.com

KEYWORD: CALIFORNIA NEW YORK TRACK INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY TRADESHOW SOURCE: Threshold Pharmaceuticals, Inc.

Copyright Business Wire 2005